Related Experiment Video
Updated: Mar 10, 2026
Enhancing Tumor Content through Tumor Macrodissection
Published on: February 12, 2022
Beyond RCHOP: A Blueprint for Diffuse Large B Cell Lymphoma Research
Grzegorz S Nowakowski1, Kristie A Blum2, Brad S Kahl2
1Department of Medicine, Mayo Clinic, Rochester, MN (GSN); Department of Internal Medicine, Ohio State University, Columbus, OH (KAB); Department of Medicine, Oncology Division, Washington University, St. Louis, MO (BSK); Wilmot Cancer Center and Division of Hematology/Oncology, University of Rochester, Rochester, NY (JWF); Coordinating Center for Clinical Trials (LB), Division of Cancer Treatment and Diagnosis (RFL), and Center for Cancer Research (WHW), National Cancer Institute, National Institute of Health, Bethesda, MD; Division of Oncology, University of Washington, Seattle WA (DGM); British Colombia Cancer Agency, Vancouver, BC (LHS); Department of Medicine, University of Virginia, Charlottesville, VA (MEW); Department of Medicine, Weil Cornell University, New York, NY (JPL); Department of Medicine, University of Chicago, Chicago, IL (SMS) nowakowski.grzegorz@mayo.edu.
Diffuse large B cell lymphoma (DLBCL) has subtypes with poor outcomes. Research priorities include identifying these subsets and developing targeted therapies for better cure rates and survival.
Area of Science:
- Hematology
- Oncology
- Genetics
Background:
- Diffuse large B cell lymphoma (DLBCL) exhibits significant molecular and biological heterogeneity, leading to diverse clinical trajectories.
- Standard chemoimmunotherapy, such as cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab (R-CHOP), shows limited efficacy in specific high-risk DLBCL subsets.
Purpose of the Study:
- To identify critical unmet needs in DLBCL research.
- To outline priorities for clinical research aimed at improving treatment outcomes for DLBCL patients.
- To focus on developing personalized strategies for both frontline and relapsed settings.
Main Methods:
- Review of current treatment failures and challenges in DLBCL.
- Identification of molecular and biological subsets with poor prognoses.
- Analysis of the need for novel agents and biomarker tools in relapsed/refractory DLBCL.
Main Results:
- Certain DLBCL subsets, including activated B cell (ABC) DLBCL, double-hit lymphomas (MYC/BCL2 translocations), dual protein-expressing lymphomas (MYC/BCL2 overexpression), older patients, and those with central nervous system involvement, have high treatment failure rates.
- There is a need for accurate molecular subset identification and evaluation of differential benefits from specific chemotherapy platforms and targeted agents.
- Effective strategies for relapsed/refractory DLBCL are lacking, highlighting the need for novel agents and biomarker development.
Conclusions:
- Prioritizing research on biologically defined risk groups is essential for improving frontline cure rates in DLBCL.
- Developing prognostic and predictive tools and individualizing new therapies are crucial for maximizing long-term survival and minimizing toxicity.
- Relapsed/refractory DLBCL presents an ideal setting for testing novel agents and biomarker discovery, necessitating a coordinated research effort.
